<DOC>
	<DOCNO>NCT00001572</DOCNO>
	<brief_summary>Patients undergo chemotherapy remission obtain , disease stable two cycle chemotherapy , progressive disease develop . Three six month completion chemotherapy , patient achieve complete clinical remission minimal disease status receive series 5 injection ( give 1-2 month apart ) vaccine consist 0.5 mg autologous tumor-derived immunoglobulin ( Id ) conjugate KLH . The vaccine administer subcutaneous QS-21 immunological adjuvant ... .</brief_summary>
	<brief_title>Vaccination Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype</brief_title>
	<detailed_description>The idiotype immunoglobulin give B cell malignancy ( Id ) serve clonal marker , previous pilot study lymphoma patient demonstrate autologous Id protein formulate immunogenic , tumor specific antigen conjugation carrier protein ( KLH ) administration emulsion-based adjuvant . The objective study : 1 ) evaluate feasibility toxicity new vaccine formulation , 2 ) evaluate cellular humoral immune response unique idiotype patient 's lymphoma . The goal study treat patient follicular lymphomas complete remission minimal residual disease chemotherapy . Six twelve month completion chemotherapy , effort reduce relapse rate ( eradicate microscopic disease resistant chemotherapy ) , patient receive one two new formulation autologous Id vaccine .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>QS 21</mesh_term>
	<mesh_term>Immunoglobulin Idiotypes</mesh_term>
	<criteria>INCLUSION CRITERIA : Sample size : 30 patient . Sex distribution : Male female . Age : Patients must great equal 18 year old . Patients must meet following eligibility criterion : Tissue diagnosis : follicular small cleave cell follicular mixed lymphoma surface IgM , IgA , IgG phenotype monoclonal heavy light chain . Pathology slide must submit NIH Pathology Department review . Stage III IV lymphoma . A single peripheral lymph node least 2x2 3x3 cm size accessible biopsy/harvest . Karnofsky status great equal 70 % . Life expectancy great 1 year . Serum creatinine less equal 1.5 mg/dl unless felt secondary lymphoma . Bilirubin le equal 1.5 mg/dl unless felt secondary lymphoma Gilbert 's disease . SGOT/SGPT le equal 3.5 x upper limit normal . Ability give inform consent . Ability return clinic adequate followup period protocol require . There gender racial / ethnic restriction patient selection . This protocol open gender racial / ethnic group . EXCLUSION CRITERIA : The presence exclusion criterion ( list ) prohibit entry onto study : Prior total body irradiation . Presence antibody HIV hepatitis B surface antigen active infectious process . Pregnant lactation . Fertile men woman must plan use effective contraception . A betaHCG level obtain woman childbearing potential . Patients previous concomitant malignancy , regardless site , except curatively treat squamous basal cell carcinoma skin , effectively treat carcinoma situ cervix . Patient unwilling give inform consent . Failure meet eligibility criterion Section 3.2 . Any medical psychiatric condition opinion protocol chairman would compromise patient 's ability tolerate treatment . Patients CNS lymphoma ( current previously treat ) eligible .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2, 2010</verification_date>
	<keyword>B-Cell Lymphoma</keyword>
	<keyword>BCL- 2 Positive Tumor</keyword>
	<keyword>Immunization</keyword>
	<keyword>Induction Chemotherapy</keyword>
	<keyword>Lymphoma Vaccine</keyword>
	<keyword>Follicular Lymphoma</keyword>
	<keyword>Tumor-Derived Immunoglobulin Idiotype</keyword>
</DOC>